(NASDAQ: OTLK) Outlook Therapeutics's forecast annual revenue growth rate of 294.82% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.68%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.94%.
Outlook Therapeutics's revenue in 2025 is $1,505,322.On average, 4 Wall Street analysts forecast OTLK's revenue for 2025 to be $285,351,054, with the lowest OTLK revenue forecast at $75,513,199, and the highest OTLK revenue forecast at $558,175,801. On average, 4 Wall Street analysts forecast OTLK's revenue for 2026 to be $1,406,411,127, with the lowest OTLK revenue forecast at $759,573,946, and the highest OTLK revenue forecast at $2,263,175,003.
In 2027, OTLK is forecast to generate $4,750,402,109 in revenue, with the lowest revenue forecast at $4,341,076,150 and the highest revenue forecast at $5,159,772,489.